118 related articles for article (PubMed ID: 16122707)
1. Peptide inhibitors of botulinum neurotoxin by mRNA display.
Yiadom KP; Muhie S; Yang DC
Biochem Biophys Res Commun; 2005 Oct; 335(4):1247-53. PubMed ID: 16122707
[TBL] [Abstract][Full Text] [Related]
2. Quinolinol and peptide inhibitors of zinc protease in botulinum neurotoxin A: effects of zinc ion and peptides on inhibition.
Lai H; Feng M; Roxas-Duncan V; Dakshanamurthy S; Smith LA; Yang DC
Arch Biochem Biophys; 2009 Nov; 491(1-2):75-84. PubMed ID: 19772855
[TBL] [Abstract][Full Text] [Related]
3. Discovery and design of novel inhibitors of botulinus neurotoxin A: targeted 'hinge' peptide libraries.
Hayden J; Pires J; Roy S; Hamilton M; Moore GJ
J Appl Toxicol; 2003; 23(1):1-7. PubMed ID: 12518330
[TBL] [Abstract][Full Text] [Related]
4. Botulinum neurotoxin serotype F: identification of substrate recognition requirements and development of inhibitors with low nanomolar affinity.
Schmidt JJ; Stafford RG
Biochemistry; 2005 Mar; 44(10):4067-73. PubMed ID: 15751983
[TBL] [Abstract][Full Text] [Related]
5. A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4.
Arndt JW; Jacobson MJ; Abola EE; Forsyth CM; Tepp WH; Marks JD; Johnson EA; Stevens RC
J Mol Biol; 2006 Sep; 362(4):733-42. PubMed ID: 16938310
[TBL] [Abstract][Full Text] [Related]
6. Light chain of botulinum neurotoxin serotype A: structural resolution of a catalytic intermediate.
Fu Z; Chen S; Baldwin MR; Boldt GE; Crawford A; Janda KD; Barbieri JT; Kim JJ
Biochemistry; 2006 Jul; 45(29):8903-11. PubMed ID: 16846233
[TBL] [Abstract][Full Text] [Related]
7. The C-terminus of botulinum neurotoxin type A light chain contributes to solubility, catalysis, and stability.
Baldwin MR; Bradshaw M; Johnson EA; Barbieri JT
Protein Expr Purif; 2004 Sep; 37(1):187-95. PubMed ID: 15294297
[TBL] [Abstract][Full Text] [Related]
8. Cloning, expression, and purification of C-terminal quarter of the heavy chain of botulinum neurotoxin type A.
Sharma S; Zhou Y; Singh BR
Protein Expr Purif; 2006 Feb; 45(2):288-95. PubMed ID: 16143544
[TBL] [Abstract][Full Text] [Related]
9. Substrate recognition strategy for botulinum neurotoxin serotype A.
Breidenbach MA; Brunger AT
Nature; 2004 Dec; 432(7019):925-9. PubMed ID: 15592454
[TBL] [Abstract][Full Text] [Related]
10. Catalytic features of the botulinum neurotoxin A light chain revealed by high resolution structure of an inhibitory peptide complex.
Silvaggi NR; Wilson D; Tzipori S; Allen KN
Biochemistry; 2008 May; 47(21):5736-45. PubMed ID: 18457419
[TBL] [Abstract][Full Text] [Related]
11. Comparison of mRNA-display-based selections using synthetic peptide and natural protein libraries.
Huang BC; Liu R
Biochemistry; 2007 Sep; 46(35):10102-12. PubMed ID: 17685586
[TBL] [Abstract][Full Text] [Related]
12. Structure of botulinum neurotoxin type D light chain at 1.65 A resolution: repercussions for VAMP-2 substrate specificity.
Arndt JW; Chai Q; Christian T; Stevens RC
Biochemistry; 2006 Mar; 45(10):3255-62. PubMed ID: 16519520
[TBL] [Abstract][Full Text] [Related]
13. Structural analysis of botulinum neurotoxin serotype F light chain: implications on substrate binding and inhibitor design.
Agarwal R; Binz T; Swaminathan S
Biochemistry; 2005 Sep; 44(35):11758-65. PubMed ID: 16128577
[TBL] [Abstract][Full Text] [Related]
14. Effects of purification on the bioavailability of botulinum neurotoxin type A.
Cheng LW; Onisko B; Johnson EA; Reader JR; Griffey SM; Larson AE; Tepp WH; Stanker LH; Brandon DL; Carter JM
Toxicology; 2008 Jul; 249(2-3):123-9. PubMed ID: 18538461
[TBL] [Abstract][Full Text] [Related]
15. Capillary electrophoresis laser-induced fluorescence for screening combinatorial peptide libraries in assays of botulinum neurotoxin A.
Laing TD; Marenco AJ; Moore DM; Moore GJ; Mah DC; Lee WE
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Nov; 843(2):240-6. PubMed ID: 16828348
[TBL] [Abstract][Full Text] [Related]
16. A refined pharmacophore identifies potent 4-amino-7-chloroquinoline-based inhibitors of the botulinum neurotoxin serotype A metalloprotease.
Burnett JC; Opsenica D; Sriraghavan K; Panchal RG; Ruthel G; Hermone AR; Nguyen TL; Kenny TA; Lane DJ; McGrath CF; Schmidt JJ; Vennerstrom JL; Gussio R; Solaja BA; Bavari S
J Med Chem; 2007 May; 50(9):2127-36. PubMed ID: 17417831
[TBL] [Abstract][Full Text] [Related]
17. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A.
Dolimbek BZ; Aoki KR; Steward LE; Jankovic J; Atassi MZ
Mol Immunol; 2007 Feb; 44(5):1029-41. PubMed ID: 16647121
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of substrate-based inhibitors of botulinum neurotoxin type B metalloprotease.
Oost T; Sukonpan C; Brewer M; Goodnough M; Tepp W; Johnson EA; Rich DH
Biopolymers; 2003; 71(6):602-19. PubMed ID: 14991672
[TBL] [Abstract][Full Text] [Related]
19. A peptide-based immunoassay for antibodies against botulinum neurotoxin A.
Atassi MZ; Dolimbek BZ; Deitiker P; Jankovic J; Aoki KR
J Mol Recognit; 2007; 20(1):15-21. PubMed ID: 16981247
[TBL] [Abstract][Full Text] [Related]
20. Detection of botulinum neurotoxin A in a spiked milk sample with subtype identification through toxin proteomics.
Kalb SR; Goodnough MC; Malizio CJ; Pirkle JL; Barr JR
Anal Chem; 2005 Oct; 77(19):6140-6. PubMed ID: 16194071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
